Trial Profile
A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2019
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms ENESTg1
- Sponsors Novartis Pharmaceuticals
- 10 May 2016 Study design changed from Parallel Assignment to Crossover Assignment
- 09 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 20 Aug 2014 Planned End Date changed from 1 May 2014 to 1 Jan 2015 as per ClinicalTrials.gov record.